Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (373)
  2. Journal Article (219)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (631)
  2. Solid Tumor Oncology Division (631)
  3. Thoracic Oncology (631)
  4. Department of Pathology and Laboratory Medicine (205)
  5. GSK Faculty (187)
  6. Human Oncology and Pathogenesis Program (156)

More Groups

People
  1. Marc Ladanyi (121)
  2. Mark Kris (89)
  3. Maria Arcila (82)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (16)
  2. 2024 (61)
  3. 2023 (67)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (84)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (118)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (77)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (631)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeted therapy outcomes in RET-rearranged lung cancers: Drug or driver?
    Journal Article

    Drilon, A.
    The Lancet Respiratory Medicine (2017)

    Fulltext@MSK | Save
  • MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers
    Meeting Abstract

    Somwar, R.; Smith, R.; Hayashi, T.; Ishizawa, K.; Charen, A. S.; Khodos, I.; Mattar, M.; He, J.; Balasubramanian, S.; Stephens, P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors
    Meeting Abstract

    Patel, M. R.; Fakih, M.; Olszanski, A. J.; Lockhart, A. C.; Drilon, A. E.; Fu, S.; Bazhenova, L.; Patel, R.; Oliver, J. W.; Multani, P. S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Next generation sequencing (NGS) in lung adenocarcinoma (LA) as a guide to treatment selection
    Meeting Abstract

    Jordan, E.; Barron, D.; Schultz, N.; Chakravarty, D.; Kris, M. G.; Rudin, C. M.; Li, B. T.; Yu, H. A.; Drilon, A. E.; Rusch, V. W.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry
    Meeting Abstract

    Gautschi, O.; Wolf, J.; Milia, J.; Filleron, T.; Carbone, D. P.; Camidge, D. R.; Shih, J. Y.; Awad, M. M.; Cabillic, F.; Peled, N.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase II basket study of the oral TRK inhibitor LOXO-101 in adult subjects with NTRK fusion-positive tumors
    Meeting Abstract

    Drilon, A. E.; Hong, D. S.; Cruickshank, S.; Deegan, M.; Ku, N.; Hyman, D. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Drilon, A. E.; Camidge, D. R.; Ou, S. H. I.; Clark, J. W.; Socinski, M. A.; Weiss, J.; Riely, G. J.; Winter, M.; Wang, S. C.; Monti, K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors
    Meeting Abstract

    Drilon, A.; Garralda, E.; Stathis, A.; Szyldergemajn, S.; Hyman, D.; Boni, V.; Griguolo, G.; Martinez, E. J.; Makker, V.; Canziani, L.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A phase II basket study of the oral TRK inhibitor LOXO-101 in adult subjects with NTRK fusion-positive tumors
    Meeting Abstract

    Drilon, A.; Hong, D.; Deeken, J.; Smith, S.; Reynolds, M.; Cruickshank, S.; Deegan, M.; Ku, N.; Hyman, D.
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • The type II switch control kinase inhibitor, DCC-2701 (altiratinib) effectively inhibits resistant NTRK kinase domain mutants
    Meeting Abstract

    Drilon, A.; Hofmann, N.; Flynn, D.; Smith, B.; Davare, M.
    European Journal of Cancer (2016)

    Fulltext@MSK | Save